Recent advances in oncolytic virus design
Clin. transl. oncol. (Print)
; Clin. transl. oncol. (Print);13(4): 229-239, abr. 2011. tab
Article
em En
| IBECS
| ID: ibc-124429
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
The cytolytic properties of viruses can be used to treat cancer. Replication of certain viruses is favoured in cancer cells, whereas others can be modified to obtain tumour specificity. This approach has evolved to become a new discipline called virotherapy. In addition, these replication-competent (oncolytic) viruses can be adapted as vectors for cancer gene therapy. The "armed" viruses show a double mechanism of action: direct destruction of cancer cells as a consequence of the lytic viral cycle, in combination with the effect of the therapeutic gene incorporated in the viral genome. Current trends in the field include strategies to increase the oncolytic potency of existing viruses; the evaluation of new candidates; the search for synergistic effects between different viruses and conventional therapies; and a rational approach to take advantage of the interplay between the viruses and the host immune system. This review summarises the most relevant achievements in recent year (AU)
Buscar no Google
Coleções:
06-national
/
ES
Base de dados:
IBECS
Assunto principal:
Vírus Oncolíticos
/
Terapia Viral Oncolítica
Limite:
Animals
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2011
Tipo de documento:
Article